Statin use and all-cancer survival: Prospective results from the Women's Health Initiative

British Journal of Cancer

Volumn 115, Issue 1, 2016, Pages 129-135

  Wang, Ange ^a   Aragaki, Aaron K ^b   Tang, Jean Y ^a   Kurian, Allison W ^a   Manson, JoAnn E ^c   Chlebowski, Rowan T ^d   Simon, Michael ^e   Desai, Pinkal ^f   Wassertheil Smoller, Sylvia ^g   Liu, Simin ^h   Kritchevsky, Stephen ⁱ   Wakelee, Heather A ^a   Stefanick, Marcia L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

3 hydroxy 3 methyl glutaryl CoA reductase inhibitor; cancer; cholesterol; HMG Co A reductase inhibitor; statins; survival

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG POTENCY; FEMALE; FOLLOW UP; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAJOR CLINICAL STUDY; MIDDLE AGED; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES; VERY ELDERLY; WOMEN'S HEALTH; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); INCIDENCE; MORTALITY; MULTICENTER STUDY; NEOPLASMS; OBSERVATIONAL STUDY; RISK ASSESSMENT;

AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MIDDLE AGED; NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; WOMEN'S HEALTH;

EID: 84973630046     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.149     Document Type: Article

References (43)

1. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. (2003). Implementation of the Women Health Initiative study design. Ann Epidemiol 13(9 Suppl): S5-S17
2. Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, Borgquist S. (2013). Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138(2): 499-508
3. Bjerre LM, LeLorier J. (2001). Do statins cause cancer? A meta-Analysis of large randomized clinical trials. Am J Med 110(9): 716-723
4. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. (2005). Use of statins and breast cancer: A meta-Analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34): 8606-8612
5. Boudreau DM, Yu O, Johnson J. (2010). Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4): 603-621
6. Browning DR, Martin RM. (2007). Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4): 833-843
7. Cambien F, Ducimetiere P, Richard J. (1980). Total serum cholesterol and cancer mortality in a middle-Aged male population. Am J Epidemiol 112(3): 388-394
8. Cardwell CR, Hicks BM, Hughes C, Murray LJ. (2015). Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 26(1): 68-78
9. Cholesterol Treatment Trialists (CTT) Collaborators. (2015). Efficacy and safety of LDL-lowering therapy among men and women: meta-Analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 385(9976): 1397-1405
10. Cholesterol Treatment Trialists (CTT) CollaboratorsMihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-Analysis of individual data from 27 randomised trials. Lancet 380(9841): 581-590
11. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S. WHI Morbidity and Mortality Committee. (2003). Outcomes ascertainment and adjudication methods in the Womens Health Initiative. Ann Epidemiol 13(9 Suppl): S122-S128
12. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. (2006). Statins and cancer risk: a meta-Analysis. JAMA 295(1): 74-80
13. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. (2008). Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18(1): 54-61
14. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. (2005). Statins and cancer prevention. Nat Rev Cancer 5(12): 930-942
15. Desai P, Chlebowski R, Cauley JA, Manson JAE, Wu CY, Martin LW, Jay A, Bock C, Cote M, Petrucelli N, Rosenberg CA, Peters U, Agalliu I, Budrys N, Abdul-Hussein M, Lane D, Luo JH, Park HL, Thomas F, Wactawski-Wende J, Simon MS. (2013). Prospective analysis of association between statin use and breast cancer risk in the Womens Health Initiative. Cancer Epidem Biomar 22(10): 1868-1876
16. Desai P, Lehman A, Chlebowski RT, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS. (2015). Statins and breast cancer stage and mortality in the Womens Health Initiative. Cancer Causes Control 26(4): 529-539
17. Fenton RG, Kung HF, Longo DL, Smith MR. (1992). Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 117(2): 347-356
18. Gauthaman K, Fong CY, Bongso A. (2009). Statins, stem cells, and cancer. J Cell Biochem 106(6): 975-983
19. Gong Z, Aragaki AK, Chlebowski RT, Manson JE, Rohan TE, Chen C, Vitolins MZ, Tinker LF, LeBlanc ES, Kuller LH, Hou L, LaMonte MJ, Luo J, Wactawski-Wende J. (2016). Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the womens health initiative. Int J Cancer 138(8): 1915-1927
20. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. (2010). Incidence of cancer and statin usage-record linkage study. Int J Cancer 126(1): 279-284
21. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. (2003). The Womens Health Initiative recruitment methods and results. Ann Epidemiol 13(9 Suppl): S18-S77
22. Herold G, Jungwirth R, Rogler G, Geerling I, Stange EF. (1995). Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2). Digestion 56(1): 57-66
23. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. (2012). A short-Term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131(3): 915-924
24. Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D, Ockene I, Simon MS. (2012). Prospective analysis of association between use of statins and melanoma risk in the Womens Health Initiative. Cancer 118(20): 5124-5131
25. Kagan A, McGee DL, Yano K, Rhoads GG, Nomura A. (1981). Serum cholesterol and mortality in a Japanese-American population: the Honolulu Heart program. Am J Epidemiol 114(1): 11-20
26. Keys A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Menotti A, Nedeljkovic S, Punsar S, Toshima H. (1985). Serum cholesterol and cancer mortality in the Seven Countries Study. Am J Epidemiol 121(6): 870-883
27. Kuoppala J, Lamminpaa A, Pukkala E. (2008). Statins and cancer: a systematic review and meta-Analysis. Eur J Cancer 44(15): 2122-2132
28. Mannello F, Tonti GA. (2009). Statins and breast cancer: may matrix metalloproteinase be the missing link. Cancer Invest 27(4): 466-470
29. Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. (2014). Statin use and breast cancer survival: a nationwide cohort study from Finland. PloS One 9(10): e110231
30. Nevadunsky NS, Van Arsdale A, Strickler HD, Spoozak LA, Moadel A, Kaur G, Girda E, Goldberg GL, Einstein MH. (2015). Association between statin use and endometrial cancer survival. Obstet Gynecol 126(1): 144-150
31. Nielsen SF, Nordestgaard BG, Bojesen SE. (2012). Statin use and reduced cancer-related mortality. N Engl J Med 367(19): 1792-1802
32. Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29
33. Simon MS, Rosenberg CA, Rodabough RJ, Greenland P, Ockene I, Roy HK, Lane DS, Cauley JA, Khandekar J. (2012). Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 22(1): 17-27
34. Singh PP, Singh S. (2013). Statins are associated with reduced risk of gastric cancer: a systematic review and meta-Analysis. Ann Oncol 24(7): 1721-1730
35. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith Jr. SC, Watson K, Wilson PW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25 Pt B): 2889-2934
36. Tan M, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C. (2013). Statins and the risk of lung cancer: a meta-Analysis. Plos One 8(2): e57349
37. Therneau TM, Grambsch PM. (2000). Modeling Survival Data: Extending the Cox Model. Springer Science and Business Media
38. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 142(2): 389-398
39. Weis M, Heeschen C, Glassford AJ, Cooke JP. (2002). Statins have biphasic effects on angiogenesis. Circulation 105(6): 739-745
40. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. (2002). HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4): 508-519
41. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. (2004). Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64(18): 6461-6468
42. Wu QJ, Tu C, Li YY, Zhu J, Qian KQ, Li WJ, Wu L. (2015). Statin use and breast cancer survival and risk: a systematic review and meta-Analysis. Oncotarget 6(40): 42988-43004
43. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. (2015). Statin use and mortality in cancer patients: Systematic review and meta-Analysis of observational studies. Cancer Treat Rev 41(6): 554-567